Phage-derived particles for in situ delivery of DNA payload into C. acnes population

Patent metadata

Field	Value
Publication number	US-12460216-B2
Application number	US-202418617782-A
Country	US
Kind code	B2
Filing date	Mar 27, 2024
Priority date	Nov 4, 2020
Publication date	Nov 4, 2025
Grant date	Nov 4, 2025

Abstract

The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.

First claim

We claim:

1. A C. acnes phage-derived particle comprising a phagemid lacking genes encoding phage structural proteins, said phagemid comprising:
a phage packaging signal allowing packaging of the phagemid in a Cutibacterium acnes phage capsid,
wherein the phage packaging signal is at least 87% identical to SEQ ID NO: 76,
a gene of interest, and
a CRISPR-Cas system.

2. The C. acnes phage-derived particle according to claim 1 , wherein the CRISPR-Cas system targets a C. acnes chromosome locus.

3. The C. acnes phage-derived particle according to claim 1 , wherein the CRISPR-Cas system targets a C. acnes plasmid locus.

4. The C. acnes phage-derived particle according to claim 1 , wherein the gene of interest is a transgene that is exogenous to C. acnes.

5. The C. acnes phage-derived particle according to claim 4 , wherein the transgene encodes a human protein.

6. The C. acnes phage-derived particle according to claim 4 , wherein the transgene encodes an antigen.

7. The C. acnes phage-derived particle according to claim 4 , wherein the transgene encodes an interleukin.

8. The C. acnes phage-derived particle according to claim 1 , wherein the phagemid further comprises an origin of replication for C. acnes and a selection marker for C. acnes.

9. The C. acnes phage-derived particle according to claim 8 , wherein the selection marker is not ermE.

10. A phagemid lacking genes encoding phage structural proteins comprising:
a phage packaging signal allowing packaging of the phagemid in a Cutibacterium acnes phage capsid,
wherein the phage packaging signal is at least 87% identical to SEQ ID NO: 76,
a gene of interest, and
a CRISPR-Cas system.

11. The phagemid according to claim 10 , wherein the CRISPR-Cas system targets a C. acnes chromosome locus.

12. The phagemid according to claim 10 , wherein the CRISPR-Cas system targets a C. acnes plasmid locus.

13. The phagemid according to claim 10 , wherein the gene of interest encodes a human protein.

14. The phagemid according to claim 10 , wherein the gene of interest encodes an antigen.

15. The phagemid according to claim 10 , wherein the gene of interest encodes an interleukin.

16. The phagemid according to claim 10 , wherein the phagemid further comprises an origin of replication for C. acnes and a selection marker for C. acnes.

17. The phagemid according to claim 16 , wherein the selection marker is not ermE.

Assignees

• Eligo Bioscience

Inventors

• Leveau Aymeric
• Canadas Blasco Inès
• Mathieu Aurélie
• Decrulle Antoine

Classifications

• C12N9/64

  derived from animal tissue · CPC title

• A61K39/02

  Bacterial antigens · CPC title

• C12N2800/80

  Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites · CPC title

• C12N2800/101

  for bacteria · CPC title

• C12N2795/10343

  viral genome or elements thereof as genetic vector · CPC title